| http://www.w3.org/ns/prov#value | - The phospholipase A1 of the present invention was a most advantageous alternative to pancreatin because on the one hand, it was more efficient (cf. patent in suit, Table 1) and, on the other hand, it could be denatured at temperatures so low as not to affect the end product of the reaction.
|
